Comorbidities in patients with Unverricht-Lundborg disease (EPM1) COMMENT

被引:3
|
作者
Sipila, Jussi O. T. [1 ,2 ]
Kalviainen, Reetta [3 ,4 ]
机构
[1] Siun Sote North Karelia Cent Hosp, Dept Neurol, Joensuu, Finland
[2] Univ Turku, Clin Neurosci, Turku, Finland
[3] Kuopio Univ Hosp, Epilepsy Ctr, Neuro Ctr, Kuopio, Finland
[4] Univ Eastern Finland, European Reference Network Rare & Complex Epileps, Inst Clin Med, Kuopio, Finland
来源
ACTA NEUROLOGICA SCANDINAVICA | 2022年 / 146卷 / 05期
关键词
clinical neurology; comorbidity; epileptic syndromes; hereditary disorders; rare epilepsies; CYSTATIN-B; FINLAND;
D O I
10.1111/ane.13706
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Unverricht-Lundborg disease (EPM1) typically leads to accumulating disability. Disability may also be caused by comorbidities but there are no data available on these. Aims of the Study: To investigate the frequency of comorbidities in EPM1. Methods: Comorbidity data of a previously described cohort of 135 Finnish patients with EPM1 were retrieved from neurological, surgical (including subspecialities), internal medicine (including subspecialities) and intensive care patient charts of the treating hospitals. Results: Mean follow-up time was 31.4 years (SD 12.4 years, range 6.8-57.8 years), during which at least one comorbidity was observed in 107 patients (79%) and three or more in 53 (39%). The most common diagnostic categories were external injuries, mental and behavioural disorders and endocrine, nutritional and metabolic diseases. The most common single comorbid diagnosis was a fracture of the ankle (in 19% of all patients). The second most common single comorbid diagnosis in the cohort was diabetes (in 13% of all patients), and the third was depression, recorded for 13% of the cohort. Malignancies and cardiovascular end-organ damage were rare, whereas phimosis/paraphimosis appeared more common than in general population. Conclusions: Patients with EPM1 often have comorbidities. Trauma and mental health risks should be especially followed and acted upon. Further studies are needed to more accurately comorbidity risks, characteristics and patient needs.
引用
收藏
页码:690 / 693
页数:4
相关论文
共 50 条
  • [21] Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients
    Tarja Joensuu
    Mervi Kuronen
    Kirsi Alakurtti
    Saara Tegelberg
    Paula Hakala
    Antti Aalto
    Laura Huopaniemi
    Nina Aula
    Roberto Michellucci
    Kai Eriksson
    Anna-Elina Lehesjoki
    European Journal of Human Genetics, 2007, 15 : 185 - 193
  • [22] Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients
    Joensuu, Tarja
    Kuronen, Mervi
    Alakurtti, Kirsi
    Tegelberg, Saara
    Hakala, Paula
    Aalto, Antti
    Huopaniemi, Laura
    Aula, Nina
    Michellucci, Roberto
    Eriksson, Kai
    Lehesjoki, Anna-Elina
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2007, 15 (02) : 185 - 193
  • [23] Identification of mutations in Cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1)
    Lalioti, MD
    Mirotsou, M
    Buresi, C
    Peitsch, MC
    Rossier, C
    Ouazzani, R
    BaldyMoulinier, M
    Bottani, A
    Malafosse, A
    Antonarakis, SE
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 60 (02) : 342 - 351
  • [24] Neuropsychological findings in patients with Unverricht-Lundborg disease
    Ferlazzo, Edoardo
    Gagliano, Antonella
    Calarese, Tiziana
    Magaudda, Adriana
    Striano, Pasquale
    Cortese, Lara
    Cedro, Clemente
    Laguitton, Virgilie
    Bramanti, Placido
    Carbonaro, Marilena
    Albachiara, Addolorata
    Fragassi, Nina
    Italiano, Domenico
    Sessa, Edoardo
    Coppola, Antonietta
    Genton, Pierre
    EPILEPSY & BEHAVIOR, 2009, 14 (03) : 545 - 549
  • [25] Perampanel in 12 patients with Unverricht-Lundborg disease
    Crespel, Arielle
    Gelisse, Philippe
    Ngoc Phuong Loc Tang
    Genton, Pierre
    EPILEPSIA, 2017, 58 (04) : 543 - 547
  • [26] Neurophysiology of Unverricht-Lundborg disease
    Franceschetti, S.
    EPILEPSIA, 2006, 47 : 231 - 231
  • [27] Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies
    Kalviainen, Reetta
    Genton, Pierre
    Andermann, Eva
    Andermann, Frederick
    Magaudda, Adriana
    Frucht, Steven J.
    Schlit, Anne-Francoise
    Gerard, Danielle
    de la Loge, Christine
    von Rosenstiel, Philipp
    EPILEPSIA, 2016, 57 (02) : 210 - 221
  • [28] Death in Unverricht-Lundborg disease
    Khiari, Hela Mrabet
    Franceschetti, Silvana
    Jovic, Nebojsa
    Mrabet, Amel
    Genton, Pierre
    NEUROLOGICAL SCIENCES, 2009, 30 (04) : 315 - 318
  • [29] Unverricht-Lundborg disease (PME1)
    Genton, P.
    REVUE NEUROLOGIQUE, 2006, 162 (8-9) : 819 - 826
  • [30] Cystatin B mutations in Unverricht-Lundborg Progressive Myoclonus Epilepsy (EPM1) patients: intrafamilial instability and genotype/phenotype correlations.
    Bespalova, IN
    Adkins, S
    Malygina, NA
    Markova, ED
    Dietrich, M
    Pranzatelli, M
    Gospe, SM
    Burmeister, M
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A327 - A327